Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry
Verena Hoffmann(Zimmer Biomet (Germany)), Rüediger Hehlmann(Heidelberg University), Richard E. Clark(The Football Association), Susanne Saußele(University of Mannheim), Andrija Bogdanović(University of Belgrade), Zuzana Sninská(University Hospital Bratislava), Fausto Castagnetti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Perttu Koskenvesa(Helsinki University Hospital), Francesco Di Raimondo(University of Catania), Paul Costeas(Deakin University), Andreas Hochhaus(Jena University Hospital), G. Schubert-Fritschle(Ludwig-Maximilians-Universität München), Noortje Thielen(Amsterdam UMC Location Vrije Universiteit Amsterdam), Michele Baccarani(University of Bologna), Hele Everaus(Tartu University Hospital), Jiřı́ Mayer(Masaryk University), Sandra Lejniece(Riga East University Hospital), Andrey Zaritskey, T. Sacha, Andrzej Hellmann(Gdańsk Medical University), Karel Indrák(Palacký University Olomouc), Laimonas Griškevičius(Vilnius University), Dubravka Sertić(University Hospital Centre Zagreb), Joerg Hasford(Ludwig-Maximilians-Universität München), Doris Lindoerfer(Zimmer Biomet (Germany)), Joëlle Guilhot(Inserm), Irena Zupan(Ljubljana University Medical Centre), Felipe Casado(Hospital Virgen de la Salud), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Bengt Simonsson(Uppsala University Hospital), Anna Turkina(National Medical Research Center for Hematology)
Cited by 1
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820